300 related articles for article (PubMed ID: 34520257)
1. Oligonucleotides Targeting DNA Repeats Downregulate
Umek T; Olsson T; Gissberg O; Saher O; Zaghloul EM; Lundin KE; Wengel J; Hanse E; Zetterberg H; Vizlin-Hodzic D; Smith CIE; Zain R
Nucleic Acid Ther; 2021 Dec; 31(6):443-456. PubMed ID: 34520257
[TBL] [Abstract][Full Text] [Related]
2. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
3. Chemical Modifications and Design Influence the Potency of
Saher O; Zaghloul EM; Umek T; Hagey DW; Mozafari N; Danielsen MB; Gouda AS; Lundin KE; Jørgensen PT; Wengel J; Smith CIE; Zain R
Nucleic Acid Ther; 2023 Apr; 33(2):117-131. PubMed ID: 36735581
[TBL] [Abstract][Full Text] [Related]
4. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
5. CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.
Zaghloul EM; Gissberg O; Moreno PMD; Siggens L; Hällbrink M; Jørgensen AS; Ekwall K; Zain R; Wengel J; Lundin KE; Smith CIE
Nucleic Acids Res; 2017 May; 45(9):5153-5169. PubMed ID: 28334749
[TBL] [Abstract][Full Text] [Related]
6. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
7. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.
Sun X; Marque LO; Cordner Z; Pruitt JL; Bhat M; Li PP; Kannan G; Ladenheim EE; Moran TH; Margolis RL; Rudnicki DD
Hum Mol Genet; 2014 Dec; 23(23):6302-17. PubMed ID: 25035419
[TBL] [Abstract][Full Text] [Related]
8. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
[TBL] [Abstract][Full Text] [Related]
9. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
10. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
11. FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat.
Goold R; Flower M; Moss DH; Medway C; Wood-Kaczmar A; Andre R; Farshim P; Bates GP; Holmans P; Jones L; Tabrizi SJ
Hum Mol Genet; 2019 Feb; 28(4):650-661. PubMed ID: 30358836
[TBL] [Abstract][Full Text] [Related]
12. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells.
Mollica PA; Zamponi M; Reid JA; Sharma DK; White AE; Ogle RC; Bruno RD; Sachs PC
J Cell Sci; 2018 Jul; 131(13):. PubMed ID: 29898922
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the Influence of TBP CAG/CAA Repeats in Conjunction with HTT CAG Repeats on Huntington's Disease Age at Onset in a Brazilian Sample.
da Silva IDS; Apolinário TA; de Andrade Agostinho L; Paiva CLA
J Mol Neurosci; 2022 May; 72(5):1116-1124. PubMed ID: 35275350
[TBL] [Abstract][Full Text] [Related]
16. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
17. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
18. The length of uninterrupted CAG repeats in stem regions of repeat disease associated hairpins determines the amount of short CAG oligonucleotides that are toxic to cells through RNA interference.
Murmann AE; Patel M; Jeong SY; Bartom ET; Jennifer Morton A; Peter ME
Cell Death Dis; 2022 Dec; 13(12):1078. PubMed ID: 36585400
[TBL] [Abstract][Full Text] [Related]
19. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.
Bañez-Coronel M; Porta S; Kagerbauer B; Mateu-Huertas E; Pantano L; Ferrer I; Guzmán M; Estivill X; Martí E
PLoS Genet; 2012; 8(2):e1002481. PubMed ID: 22383888
[TBL] [Abstract][Full Text] [Related]
20. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
